Format

Send to

Choose Destination
Eur Respir Rev. 2017 Jun 28;26(144). pii: 170044. doi: 10.1183/16000617.0044-2017. Print 2017 Jun 30.

Cell therapy for lung disease.

Author information

1
Preclinical Development, Apceth Biopharma GmbH, Munich, Germany f.hermann@apceth.com.
2
Preclinical Development, Apceth Biopharma GmbH, Munich, Germany.

Abstract

Besides cancer and cardiovascular diseases, lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions no effective and curative treatment options are available. Cell therapies offer a novel therapeutic approach due to their inherent anti-inflammatory and anti-fibrotic properties. Mesenchymal stem/stromal cells (MSC) are the most studied cell product. Numerous preclinical studies demonstrate an improvement of disease-associated parameters after MSC administration in several lung disorders, including chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Furthermore, results from clinical studies using MSCs for the treatment of various lung diseases indicate that MSC treatment in these patients is safe. In this review we summarise the results of preclinical and clinical studies that indicate that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless, further investigations are required.

PMID:
28659506
DOI:
10.1183/16000617.0044-2017
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center